HC Wainwright 2nd Annual Psychedelics Conference, BACK TO

VANCOUVER, British Columbia, December 03, 2021 (GLOBE NEWSWIRE) – BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company focused on the development and commercialization of cutting-edge treatments for mental disorders, is pleased to announce that Dr Ahmad Doroudian will attend the HC Wainwright 2sd Annual Conference on Psychedelics. The event will be held virtually on Monday, December 6, 2021.

The theme of the conference is “Positioning for the psychedelic return in mental health care and beyond”. This event will bring together all the major thought leaders and businesses in the space to discuss this paradigm shift.

Dr. Doroudian’s presentation will be available from Monday, December 6 at 7 a.m. EST. BetterLife invites you to register and attend this event.

Conference registration and more information are available at https://hcwevents.com/psychedelics/. For any inquiries, please contact HC Wainwright at [email protected]

About BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company focused primarily on the development and commercialization of two compounds, TD-0148A and TD-010, to treat neuropsychiatric and neurological disorders.

TD-0148A, which is the subject of preclinical studies and enabling IND, is a non-hallucinogenic and uncontrolled derivative of LSD in development and is unique in that it is not regulated and may therefore be self-administered. BetterLife’s synthetic patent for TD-0148A removes regulatory hurdles and its patent pending for the composition and method of use covers the treatment of depression, cluster headaches, post-traumatic stress disorder and ‘other neuro-psychiatric and neurological disorders. The global depression drug market reached US $ 12.41 billion in 2019 and is expected to reach nearly US $ 25 billion by 2030. According to the WHO, depression is one of the leading causes of disability, affecting approximately 265 million people worldwide.

TD-010, which is the subject of preclinical studies and enabling IND, is based on honokiol, the active anxiolytic ingredient in magnolia bark. BetterLife’s method of use and formulation patent covers the treatment of anxiety-related disorders, including benzodiazepine dependence and insomnia. The global benzodiazepines market is expected to reach US $ 4.15 billion in 2017 (up from US $ 3.48 billion in 2019) at a CAGR of 2.25%.

BetterLife also has a drug candidate for the treatment of viral infections such as COVID-19 and is researching strategic alternatives for further development.

For more information, please visit BetterLife Pharma.

Contact details

BetterLife Pharma:

Ahmad Doroudian, Chairman and CEO
Email: [email protected]
Phone: 1-604-221-0595

For more information please contact:

David Melles, Head of Investor Relations
Email: [email protected]
Phone: 1-778-887-1928

Caution regarding forward-looking statements

No stock exchange has reviewed or accepts responsibility for the adequacy or accuracy of the contents of this press release. This press release contains forward-looking statements relating to product development, licensing, marketing and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by words such as “will”, “may”, “should”, “anticipate”, “expect” and similar expressions. All statements other than statements of historical fact included in this press release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements. Significant factors that could cause actual results to differ materially from the Company’s expectations include failure to comply with the conditions of the relevant stock exchange (s) and other risks detailed from time to time in documents filed by the Company. Company with securities regulations. The reader is cautioned that the assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those expected, due to many known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on forward-looking information. This information, although considered reasonable by management at the time of its preparation, may prove to be incorrect and actual results may differ materially from those anticipated. The forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release and the Company will publicly update or revise all included forward-looking statements as expressly required by applicable law.


Source link